2型糖尿病合并消化道恶性肿瘤患者的临床特征及影响因素分析

来源期刊：广州医药 | 57-61 发布时间：2021-11-28 收稿时间：2025/11/13 17:39:38 阅读量：26

作者：: 侯泽鑫,

李思源,

蔺茹君,

冀雪姣,

向清淋,

李军,

关键词：: 消化道恶性肿瘤 T2DM T2DM合并消化道恶性肿瘤影响因素; Gastrointestinal malignancy T2DM T2DM with gastrointestinal malignancy Factors

DOI：: 10.3969/j.issn.1000-8535.2020.06.012

收稿时间：: 2020-01-12
修订日期：
接收日期：
引用总数：: 0

目的分析石河子地区2型糖尿病(T2DM)合并消化道恶性肿瘤患者的临床特征,探讨T2DM合并消化道恶性肿瘤的影响因素。方法 ①纳入我院2015年至今消化道恶性肿瘤患者为研究对象。根据OGTT结果或既往有无T2DM病史分为三组:健康对照组(A组),消化道恶性肿瘤组(B组),T2DM合并消化道恶性肿瘤组(C组)。②全自动生化分析仪测定血清中糖脂代谢指标,化学发光法测定血清甲胎蛋白(AFP)等肿瘤标志物,分析其临床特征,进行组间比较,并探讨其影响因素。采用SPSS 22.0软件处理数据,并进行方差分析;影响因素采用Logistic回归分析;假设检验水准α＝0.05,双侧检验P<0.05差异有统计学意义。结果 ①基线资料比较显示:A组310例(男女比138/172),年龄(52.96±10.98)岁;B组513例(男女比343/170),胃癌患者居多(26.90%),年龄(62.26±12.34)岁;C组134例(男女比80/54),肝癌患者较多(26.12%),年龄(66.78±10.47)岁;与A组相比,B组与C组男性患者较多,年龄较大。②组间基线资料比较显示:三组的性别、年龄存在统计学差异(P<0.001)。③协方差分析消除影响因素后:与A组相比,B组及C组的TG、 TC、HDL-c降低(P<0.001);FPG、AFP、CEA、CA12-5、CA15-3、CA19-9、CA72-4升高(P<0.01)。④Logistic回归分析后结果显示:FPG为消化道恶性肿瘤发生的独立危险因素(OR=1.204);年龄是消化道恶性肿瘤及T2DM合并消化道恶性肿瘤发生的危险因素(OR=1.072,1.105),HDL-c为消化道恶性肿瘤及T2DM合并消化道恶性肿瘤发生的保护因素(OR=0.200,0.111);结论老年男性T2DM患者易发生消化道恶性肿瘤。因此,对于高龄男性T2DM患者,尤其是HDL-c降低的情况下,应进行相关筛查,以早期防治消化道恶性肿瘤的发生发展。

Objective To analyze the clinical characteristics of patients with type 2 diabetes mellitus (T2DM)complicated with gastrointestinal malignancy in Shihezi area, and investigate the influencing factors of T2DM complicated with gastrointestinal malignancy. Methods ①Patients with malignant tumors of the digestive tract in our hospital from 2015 to the present have been included in the study. They were divided into three groups based on OGTT results or previous history of T2DM: healthy control group (group A), gastrointestinal malignant tumor group (group B), and T2DM combined gastrointestinal malignant tumor group (group C). ②Automatic biochemical analyzer measured serum glucose and lipid metabolism indicators, chemiluminescence method was used to measure serum alpha-fetoprotein (AFP)and other tumor markers, to analyze its clinical characteristics, make a comparaison between groups, and explore its influencing factors. The data was processed with SPSS 22.0 software and analysis of variance was performed; the influencing factors were analyzed by logistic reg-ression; hypothesis test level = 0.05, and the two-sided test P <0.05 was statistically significant. Results ①Comparison of baseline data showed that 310 cases (male/female 138/172)in group A were (52.96±10.98)years old. In group B, 513 patients (male/female 343/170)were diagnosed with gastric cancer (26.90%), aged (62.26±12.34)years. There were 134 cases in group C (male/female 80/54), with more liver cancer patients (26.12%), and the age was (66.78±10.47)years. Compared with group A, group B and group C had more male patients and were older. ②Comparison of baseline data among groups showed there were statistical differences in gender and age among the three groups (P<0.001). ③After covariance analysis eliminated influencing factors: compared with group A, TG, TC and HDL-c were decreased in group B and group C (P<0.001). FPG, AFP, CEA, CA12-5, CA15-3, CA19-9, and CA72-4 increased (P<0.01). ④Logistic regression analysis results: FPG was an independent risk factor for gastrointestinal malignancy (OR=1.204). Age wss a risk factor for gastrointestinal malignancy and T2DM complicated with gastrointestinal malignancy (OR=1.072, 1.105), HDL-c was the protective factor (OR=0.200, 0.111). Conclusion Elderly male T2DM patients are prone to gastrointestinal malignancies. Therefore, for elderly men with T2DM, especially when HDL-c is reduced, relevant screening should be performed to prevent and control the occurrence and development of gastrointestinal malignant tumors in the early stage.

1、董大庆,李炳庆,何培元. 血脂在结直肠癌中应用价值的研究[J]. 世界最新医学信息文摘,2019,19(6):199-201.

2、 WANG C, WANG X, GONG G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies [J]. Int J Cancer, 2012, 130(7):1639-1648.

3、陶然,周金意,苏健,等. 江苏省成年人血脂异常与糖尿病关系[J]. 中国公共卫生,2015,31(5):558-562.

4、陈丹,张伟斌,吴敏华. 老年2型糖尿病血糖波动性及其与血清肿瘤标志物水平及结直肠癌的关系分析[J]. 广东医学,2017,38(21):3299-3301.

5、 STEPHANIE C,HARDY R W. The metabolic syndrome: a high-risk state for cancer? [J]. Am J Pathol,2006,169(5): 1505-1522.

6、秦娟,吴艳,朱晓荣,等. 2型糖尿病合并恶性肿瘤患者代谢相关因素与肿瘤临床特征的相关性分析[J]. 肿瘤预防与治疗,2018,31(2):99-102.

7、代伟伟,刘正新,徐宝宏. 肝硬化和肝癌患者血清CA125、CA199、AFP和CEA水平变化[J]. 实用肝脏病杂志,2017,20(1):81-84.

8、谢晓英,钟日辉,刘晓强,等. 糖尿病患者血清肿瘤标志物水平及其与并发症的关系[J]. 中国卫生检验杂志,2015,25(7):1005-1007.

9、郁肖夫,郑晓. 糖类抗原CA125 CA199 CA724癌胚抗原对大肠癌的诊断价值[J]. 中国药物与临床,2019,19(3):395-397.

10、揭育丽,梁伟娟. 血清CA19-9对胰腺癌及胆道疾病临床诊断的价值[J]. 中国热带医学,2009,9(5):871-872.

11、秦娟,吴艳,朱晓荣,等. 2型糖尿病并发恶性肿瘤风险的Logistic回归分析[J]. 肿瘤预防与治疗,2017,30(6):433-436,452.

12、 FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):359-386.

13、 de BRUIJN K M J, ARENDS L R, HANSEN B E, et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer[J]. Br J Surg, 2013, 100(11):1421-1429.

14、 SHIMOYAMA S. Diabetes mellitus carries a risk of gastric cancer: A meta-analysis[J]. World J Gastroenterol, 2013, 19(40):6902-6910.

15、 BEN Q, XU M, NING X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies[J]. Eur J Cancer, 2011, 47(13):1931-1937.

16、 FORD H E R, MARSHALL A, BRUDGEWATER J A, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial[J]. Lancet Oncol, 2014, 15(1):78-86.

17、 THUSS-PATIENCE P C, KRETZSCHMAR A, BICHEY D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III stuhe dy of the arbeitsgemeinschaft internistisconkologie (AIO)[J]. Eur J Cancer, 2011, 47(15):2306-2314.

18、 KANG J H, LEE S I, LIM D H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase iii trial comparing chemotherapy plus best supportive care with best supportive care alone[J]. J Clin Oncol, 2012, 30(13):1513-1518.

19、王莹莹,马骁,杨万水,等. 2型糖尿病与消化系统恶性肿瘤队列研究的Meta分析[J]. 中国肿瘤,2013,22(11):845-857.

20、 BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2018, 68(6):394-424.

21、王蕾,吴益康,马骏,等. 2型糖尿病患者的恶性肿瘤发病风险:基于浙江省嘉兴市糖尿病管理数据的回顾性队列研究[J]. 肿瘤,2019,39(07):548-557.

22、 WANGQING C, KEXIN S, RONGSHOU Z, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.

23、 WANG L M, GAO P, ZHANG M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in china in 2013[J]. JAMA,2017,317(24):2515-2523.

24、 OGURTSOVA K, da ROCHA FERNANDES J D, HUANG Y, et al. IDF Diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017(128):40-50.